Drug Trial Radar · NCT02981368
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Aug 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
385
Actual
Start
Nov 2016
Primary completion
Jul 2018
Study completion Jul 2018
Sponsor
- Lead sponsor
- Progenics Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 5, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the safety and diagnostic performance of 18F-DCFPyL Injection in patients with at least high risk prostate cancer who are planned for radical prostatectomy with lymphadenectomy (Cohort A) or in patients with locally recurrent or metastatic disease willing to undergo biopsy (Cohort B). Cohort B is complete and no longer recruiting subjects.
Conditions
- Prostate Cancer
Interventions
18F-DCFPyL InjectionDrug
A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
PET/CT imagingDiagnostic test
PET/CT imaging will be acquired 1-2 hours post-PyL injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Specificity of 18F-DCFPyL PET/CT Imaging to Detect Metastatic Prostate Cancer Within the Pelvic Lymph Nodes Relative to Histopathology in High Risk Prostate Cancer Participants (Cohort A)Time frame: Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.
- Sensitivity of 18F-DCFPyL PET/CT Imaging to Detect Metastatic Prostate Cancer Within the Pelvic Lymph Nodes Relative to Histopathology in High Risk Prostate Cancer Participants (Cohort A)Time frame: Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
University of California at San Francisco (UCSF) - Mt. Zion Hospital
San Francisco, California
Yale University Department of Radiology and Biomedical Imaging
New Haven, Connecticut
University of Chicago
Chicago, Illinois
Johns Hopkins University
Baltimore, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
University of Michigan Cancer Center
Ann Arbor, Michigan
Washington University Mallinckrodt Institute of Radilogy
St Louis, Missouri
Memorial Sloan Kettering Cancer Center
New York, New York
Centre Hospitalier Universitaire de Quebec (CHUQ)
Québec, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.